We would like to congratulate Jonas et al1 ontheir recent article, which compared the treatment of diabetic macular edemawith intravitreal triamcinolone acetonide with standard grid macular laserphotocoagulation. There are a few issues we would like to raise and discuss.The first is about the optimum dose of intravitreal triamcinolone acetonide.Jonas and coauthors used 20 to 25 mg in their studies, whereas other authorsof recent articles used 2 to 4 mg.2,3 Wealso use 2 to 4 mg in our practice. In this study, the authors chose 25 mgbecause it was their customary dose. May we ask, what is the original rationalebehind this choice?
Chan CKM, Chan W, Cheung BTO, Yuen CYF, Lee VYW, Lam DSC. Intravitreal Injection of Triamcinolone for Diffuse Diabetic MacularEdema. Arch Ophthalmol. 2004;122(7):1083–1085. doi:10.1001/archopht.122.7.1083-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: